Rapid medical weight loss fuels surge in facial aesthetics, Allergan data shows

Rapid medical weight loss fuels surge in facial aesthetics, Allergan data shows

By: IPP Bureau

Last updated : March 05, 2026 4:21 pm



Recent data reveal that patients undergoing MWL are entering aesthetic practices with unique needs tied to facial structure and skin quality


Allergan Aesthetics, an AbbVie company, is spotlighting a dramatic shift in the aesthetics landscape as Medical Weight Loss (MWL) treatments reshape patient behaviour and treatment demand—particularly around facial volume loss.
 
"Allergan Aesthetics is committed to equipping our customers with data-driven insights, education, and consultation tools to help guide patients safely and effectively through these changes," said Glen Curran, Senior Vice President at Allergan Aesthetics. 
 
"We're seeing this new patient population enter aesthetics with different concerns, different goals, and a strong desire for individualized, long-term treatment and care, particularly when it comes to restoring facial balance and volume."
 
Recent data reveal that patients undergoing MWL are entering aesthetic practices with unique needs tied to facial structure and skin quality—many for the first time. Rapid weight loss can accelerate visible facial changes, making early consultation and proactive treatment planning critical. 
 
Hyaluronic acid fillers are emerging as a key solution, helping patients restore volume and maintain natural-looking results that complement their overall transformation.
 
Consumer interest in aesthetics is rising sharply: 40% of MWL patients are now considering professional aesthetic treatments in physicians’ offices or medspas. Meanwhile, aesthetic practices themselves are becoming primary touchpoints for MWL patients. Six in ten consumers using GLP-1 medications now receive them from healthcare providers who also offer aesthetic treatments—a jump from roughly half just a year ago.
 
Data: Facial volume loss leads the aesthetic impacts, affecting 61% of GLP-1 patients, followed by skin laxity (50%) and wrinkles/folds (35%).
 
Hyaluronic acid dermal fillers are the top nonsurgical modality, with 81% of healthcare providers citing them as the primary treatment after GLP-1–related weight loss.
 
One-third of physicians report that GLP-1 usage has increased overall dermal filler volume in their practices.
 
"As a dermatologist, I've seen firsthand how medical weight loss can significantly impact the face," said Dr Joely Kaufman, a board-certified dermatologist in Miami. "This data reflects what we're seeing in practice – patients who are excited about their weight loss success are looking for personalized, medically appropriate solutions that restore balance and confidence."

Allergan Aesthetics AbbVie

First Published : March 05, 2026 12:00 am